For the next 18months, they'd need over $200mil to housing all the trials, one Ph3, one Ph2B (the cohort size would be bigger than a usual ph2B as this is fast track, trying to take down the fruit before going ph3), multiple ph2 and a potential ph1 for autoimmune.
And that $200mil is only going to sustain for maybe the primary end point of those big trials. For bringing everything to final read out, maybe asking another $200mil?
Lets say we just fulfill the first part of the trial and get $200mil ready, and that means extra $100mil on top of the funds now.
The current market cap sits around $330mil and even they do the next round CR by the whole market recovers a bit when MC sits around $400mil, then asking $100mil extra dilution plus they need to offer discount, this means further 25%+ dilution on the book.
Call this insane if they think they can do this solo........
- Forums
- ASX - By Stock
- Ann: Immutep Quarterly Activities Report and Appendix 4C
For the next 18months, they'd need over $200mil to housing all...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
32.0¢ |
Change
0.015(4.92%) |
Mkt cap ! $446.6M |
Open | High | Low | Value | Volume |
30.0¢ | 32.0¢ | 30.0¢ | $780.2K | 2.483M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
21 | 239610 | 31.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.0¢ | 141028 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 270768 | 0.315 |
12 | 273242 | 0.310 |
12 | 121563 | 0.305 |
16 | 521609 | 0.300 |
13 | 327330 | 0.295 |
Price($) | Vol. | No. |
---|---|---|
0.320 | 143018 | 12 |
0.325 | 155667 | 6 |
0.330 | 395012 | 7 |
0.335 | 166448 | 8 |
0.340 | 87641 | 6 |
Last trade - 12.39pm 24/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online